A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

التفاصيل البيبلوغرافية
العنوان: A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
المؤلفون: Carol Aghajanian, Yulei Wang, Jill M. Spoerke, Shan Lu, Ling-Yuh Huw, Ursula A. Matulonis, Rui Zhu, Vicky Makker, Houston Gilbert, Hema Parmar, Ling Ma, Fernando O. Recio, Mark R. Lackner, Joseph A. Ware, Jennifer O. Lauchle, Hartmut Koeppen
المصدر: Cancer. 122:3519-3528
بيانات النشر: Wiley, 2016.
سنة النشر: 2016
مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, business.industry, Endometrial cancer, Phases of clinical research, Common Terminology Criteria for Adverse Events, medicine.disease, Rash, Gastroenterology, Surgery, Discontinuation, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, Tolerability, 030220 oncology & carcinogenesis, Internal medicine, medicine, Carcinoma, medicine.symptom, business, Adverse effect
الوصف: BACKGROUND The current single-arm, open-label trial was designed to evaluate the activity of apitolisib (GDC-0980), a dual phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor, in patients with advanced endometrial cancer (EC). METHODS Patients with recurrent or persistent EC who were treated with 1 to 2 prior lines of chemotherapy but no prior PI3K/mTOR inhibitor received oral apitolisib at a dose of 40 mg daily during 28-day cycles until disease progression or intolerable toxicity occurred. Patients with type I/II diabetes who required insulin were excluded. The primary endpoints were progression-free survival (PFS) at 6 months and objective response rate. RESULTS A total of 56 women were enrolled, including 13 (23%) with well-controlled diabetes. Reasons for discontinuation were disease progression (24 patients; 43%), adverse events (13 patients; 23%), and withdrawal by subject (12 patients; 21%). Grade 3/4 apitolisib-related adverse events were hyperglycemia (46%), rash (30%), colitis (5%), and pneumonitis (4%) (toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]). The PFS rate at 6 months was 20% (Kaplan-Meier estimate; 95% confidence interval [95% CI], 7%-33%). The objective response rate was 6% (confirmed). The median PFS was 3.5 months (95% CI, 2.7-3.7 months) and the median overall survival was 15.7 months (95% CI, 9.2-17.0 months). Nineteen patients discontinued the study before the first tumor assessment. Dose reductions were required for 4 diabetic (31%) and 18 nondiabetic (42%) patients. Comprehensive molecular profiling of 46 evaluable archival tumor samples demonstrated that 57% of patients had at least 1 alteration in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphatase and tensin homolog (PTEN), or AKT1. All 3 patients with a confirmed response had at least 1 alteration in a PI3K pathway gene. CONCLUSIONS The antitumor activity noted with the use of a dose of 40 mg of apitolisib daily was limited by tolerability, especially in diabetic patients. Patients with PI3K pathway mutations may have derived enhanced benefit from apitolisib. Cancer 2016. © 2016 American Cancer Society.
تدمد: 0008-543X
DOI: 10.1002/cncr.30286
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::5d33de98628b96ee8ea339b75a6df36d
https://doi.org/10.1002/cncr.30286
Rights: OPEN
رقم الانضمام: edsair.doi...........5d33de98628b96ee8ea339b75a6df36d
قاعدة البيانات: OpenAIRE
الوصف
تدمد:0008543X
DOI:10.1002/cncr.30286